



KAREN L. SMITH, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2019-14

DATE: June 13, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF DOLUTEGRAVIR/LAMIVUDINE (DOVATO®)

Effective May 24, 2019, the fixed dose combination tablet of dolutegravir 50 mg and lamivudine 300 mg (**DOVATO®**) has been added to the ADAP formulary.

Dolutegravir 50 mg is an integrase strand transfer inhibitor and lamivudine 300 mg is a nucleoside reverse transcriptase inhibitor used to treat HIV infection. Dovato® is the first two-drug, fixed-dose, complete antiretroviral (ARV) treatment regimen that can be used in the treatment of HIV-1-infected adults who are treatment naïve and with no history of resistance to dolutegravir or lamivudine. Dovato® received U.S. Food and Drug Administration approval on April 8, 2019.

In accordance with California Health and Safety Code § 120955(a)(2), the ADAP Medical Advisory Committee voted to recommend the addition of Dovato® to the ADAP formulary.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](#) has been updated to reflect the addition of Dovato®. The updated formulary can be accessed at the following URL: (<https://cdph.magellanrx.com/member/documents>).

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

A handwritten signature in blue ink, appearing to read 'A. Barraza', with a long horizontal flourish extending to the right.

Adrian Barraza
ADAP Program, Policy, and Fiscal Section Chief
California Department of Public Health